D. Western Therapeutics Institute, Inc.

DB:6DW Stock Report

Market Cap: €17.9m

D. Western Therapeutics Institute Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Yuichi Hidaka

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure15.8yrs
CEO ownership7.8%
Management average tenureno data
Board average tenure10.5yrs

Recent management updates

Recent updates

CEO

Yuichi Hidaka (51 yo)

15.8yrs

Tenure

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka serves as a Director at Actual Eyes Inc. He se...

Board Members

NamePositionTenureCompensationOwnership
Yuichi Hidaka
President15.8yrsno data7.82%
¥ 1.4m
Sayako Matsubara
CFO & Director1.5yrsno data0.015%
¥ 2.7k
Yoshiyuki Yamakawa
Independent Outside Director14.5yrsno data0.048%
¥ 8.6k
Eisaku Nakamura
Independent Outside Director6.4yrsno data0.00027%
¥ 48.3
Masaaki Suzuki
Member of Scientific Advisory Boardno datano datano data
Tasuku Honjyo
Member of Scientific Advisory Boardno datano datano data
Masato Shibuya
Member of Scientific Advisory Boardno datano datano data
Arata Uemura
Member of Scientific Advisory Boardno datano datano data
Anthony Means
Member of Scientific Advisory Boardno datano datano data
Walter Chazin
Member of Scientific Advisory Boardno datano datano data
Yasuhiko Ito
Member of Scientific Advisory Boardno datano datano data
Yasumi Uchida
Member of Scientific Advisory Boardno datano datano data

10.5yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 6DW's board of directors are seasoned and experienced ( 10.5 years average tenure).